Cancer immunotherapy

Todos Medical Announces NFL Hall of Famer Michael Irvin as Tollovid™ Sports Ambassador for #TolloUp Campaign

Retrieved on: 
Friday, September 16, 2022
Virus, Legislation, Pressure, Lymphocyte, Patient, MERS, U.S. Securities and Exchange Commission, Technology, TMB-2, Research, Monocyte, PCR, Synthase, Time, COVID-19, Knowledge, Company, COVID, TBIA, Infection, Amazon, Sport, Apoptosis, Severe acute respiratory syndrome coronavirus 2, OTCQB, CEO, Method, GLOBE, IRB, Immune system, Cancer, Neurodegeneration, Plasma, Alzheimer's disease, Ministry of Culture, Information, Sports and Youth Policy (Kyrgyzstan), Athlete, Cancer immunotherapy, Brain, NFL, Ambassador, Solution, Biotechnology, Cell cycle, Neuron, Online shopping, Pharmaceutical industry, Medical imaging, Pharma

A recent market research study showed that 90%+ of both acute infection and Long COVID customers indicated they benefitted from Tollovid.

Key Points: 
  • A recent market research study showed that 90%+ of both acute infection and Long COVID customers indicated they benefitted from Tollovid.
  • Michael Irvin is one of the greatest NFL players of all time and an all-time competitor, said Gerald E. Commissiong, President & CEO of Todos Medical.
  • With this in mind, Tollovid is an ideal solution to help support healthy immune function and guard against infections that can derail a season.
  • Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support.

Todos Medical Announces Preprint of Long COVID Case Study Participant with Confirmed Microclot and Hyperactivated Platelets who Benefitted from Tollovid

Retrieved on: 
Thursday, September 15, 2022
ADS, Virus, Legislation, Pressure, Lymphocyte, Patient, MERS, U.S. Securities and Exchange Commission, Preprint, Technology, TMB-2, Research, RN, Monocyte, PCR, Synthase, COVID-19, Knowledge, Company, TBIA, Amazon, Apoptosis, PASC, Severe acute respiratory syndrome coronavirus 2, OTCQB, Method, ResearchGate, GLOBE, IRB, Immune system, Cancer, Neurodegeneration, Plasma, Alzheimer's disease, Cancer immunotherapy, Brain, Solution, Biotechnology, Cell cycle, Neuron, Pharmaceutical industry, Online shopping, Medical imaging, COVID, Pharma

While further research needs to be conducted regarding the underlying pathophysiology of Long COVID, many studies have revealed the presence of microclots in plasma samples from Long COVID patients.

Key Points: 
  • While further research needs to be conducted regarding the underlying pathophysiology of Long COVID, many studies have revealed the presence of microclots in plasma samples from Long COVID patients.
  • In the following case study, we document the journey of a Long COVID patient in whom microclots and hyperactivated platelets are observed.
  • Following standard anti-coagulation therapy, supplementation with Tollovid, a botanical 3CL protease inhibitor, is initiated, which helps improve the patients overall trajectory of recovery.
  • Preliminary data from an ongoing IRB-waived study of customers who used the products to assist with their COVID and Long COVID were recently announced.

Todos Medical & The Alchemist’s Kitchen to Host “Long COVID: An Integrated Approach” Event Benefitting Survivor Corps

Retrieved on: 
Tuesday, September 13, 2022
Virus, Legislation, Pressure, Internal medicine, Lymphocyte, Patient, MERS, U.S. Securities and Exchange Commission, Technology, TMB-2, Human, Research, Monocyte, PCR, Synthase, Textbook, COVID-19, Knowledge, University School, Company, COVID, Donation, Survivor Corps, TBIA, Amazon, Apoptosis, Autoimmunity, Severe acute respiratory syndrome coronavirus 2, OTCQB, Harvard University, Method, IRB, Immune system, Cancer, Neurodegeneration, Plasma, Alzheimer's disease, Allergy, Alchemy, Cancer immunotherapy, Brain, Biotechnology, Cell cycle, Neuron, Plant, Online shopping, Pharmaceutical industry, Medical imaging, Pharma

Diana Berrent - Founder of Survivor Corps, Long Covid Survivor

Key Points: 
  • Diana Berrent - Founder of Survivor Corps, Long Covid Survivor
    To learn more about the 3CL protease in SARS-CoV-2 replication, please visit www.3clpro.com .
  • While scrambling to get medical information and testing, she became an advocate and activist for herself and others.
  • As a self-described Canary in the COVID Coalmine, she vowed to amplify her voice as she navigated through this virus odyssey.
  • She documented both her illness and recovery through her Coronavirus Diary , giving the world a glimpse of her struggles and process.

Todos Medical’s 3CL Protease Inhibitor Supplement Tollovid™ Featured in Wellness Magazine

Retrieved on: 
Tuesday, September 13, 2022
Virus, Legislation, Pressure, Lymphocyte, Patient, MERS, U.S. Securities and Exchange Commission, Technology, TMB-2, Research, Monocyte, PCR, Synthase, COVID-19, Knowledge, Company, COVID, TBIA, Amazon, Apoptosis, Infection, Autoimmunity, Severe acute respiratory syndrome coronavirus 2, OTCQB, CEO, Method, GLOBE, IRB, Immune system, Cancer, Neurodegeneration, Plasma, Alzheimer's disease, CCR5, Cancer immunotherapy, Brain, Solution, Biotechnology, Cell cycle, Neuron, Pharmaceutical industry, Online shopping, Medical imaging, Long COVID, Pharma

Given that Tollovid is the only 3CL protease inhibitor supplement on the market, it has an important role to play in helping people right now who are dealing with these issues.

Key Points: 
  • Given that Tollovid is the only 3CL protease inhibitor supplement on the market, it has an important role to play in helping people right now who are dealing with these issues.
  • Tollovid and Tollovid Daily are oral dietary supplement products made from natural ingredients that help support and maintain healthy immune function and also have potent 3CL protease inhibition properties based upon in vitro functional assays that show strong inhibition of 3CL protease activity.
  • Tollovid and Tollovid Daily bind to the active site of the 3CL protease.
  • 3CL Pharma, through Todos brand, has commercialized the 3CL protease inhibitor immune support dietary supplement Tollovid in the United States, is developing the dual mechanism 3CL protease inhibitor and anti-cytokine therapeutic drug candidate Tollovir, while also developing the 3CL protease diagnostic TolloTest.

Society for Immunotherapy of Cancer to Host Intensive Cancer Immunotherapy and Tumor Immunology Educational Program

Retrieved on: 
Friday, August 26, 2022
Cancer, Immunotherapy, Program, Cancer immunotherapy, YouTube, Society for Immunotherapy of Cancer, LinkedIn, Science, Curriculum, Education, Faculty, MD, Twitter, Society, Patient, SITC, Pharmaceutical industry, Medicine

MILWAULKEE, Aug. 26, 2022 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the fifth annual Cancer Immunotherapy Winter School, a comprehensive educational program, taking place Jan. 17-21, 2023, in Austin, TX and virtually.

Key Points: 
  • The Society for Immunotherapy of Cancer (SITC) is pleased to announce the fifth annual Cancer Immunotherapy Winter School, a comprehensive educational program, taking place Jan. 17-21, 2023, in Austin, TX and virtually.
  • MILWAULKEE, Aug. 26, 2022 /PRNewswire-PRWeb/ -- The Society for Immunotherapy of Cancer (SITC) is pleased to announce the fifth annual Cancer Immunotherapy Winter School, a comprehensive educational program, taking place Jan. 17-21, 2023, in Austin, TX and virtually.
  • The SITC Cancer Immunotherapy Winter School will feature leading experts in the field who will provide attendees with a deep understanding of the core principles and clinical applications of tumor immunology and cancer immunotherapy.
  • Established in 1984, the Society for Immunotherapy of Cancer (SITC) is a nonprofit organization of medical professionals dedicated to improving cancer patient outcomes by advancing the development, science and application of cancer immunotherapy and tumor immunology.

Todos Medical Announces Preprint of Data from First 100 Participants in IRB-waived Market Research Study of Supplementation with Tollovid in Long COVID

Retrieved on: 
Friday, August 19, 2022
U.S. Securities and Exchange Commission, GLOBE, Brain, Knowledge, RN, Research, Method, Patient, Monocyte, TBIA, Immune system, Neuron, Technology, Cell cycle, Heel, Lymphocyte, Biotechnology, Neurodegeneration, IRB, Pressure, OTCQB, Amazon, LHS, Preprint, Apoptosis, PASC, Acute respiratory distress syndrome, Cancer, Synthase, MERS, COVID-19, Infection, Virus, ResearchGate, HIV, Solution, Severe acute respiratory syndrome coronavirus 2, HCV, PCR, NEMO, Medicine, Legislation, Plasma, Quality of life, Company, TMB-2, Alzheimer's disease, Cancer immunotherapy, Pharmaceutical industry, Vaccine, Medical imaging, Rotavirus, Pharma, COVID

Participants in the study are primarily patients with Post-Acute Sequelae of COVID (PASC, or Long COVID) as well as participants with acute COVID infection.

Key Points: 
  • Participants in the study are primarily patients with Post-Acute Sequelae of COVID (PASC, or Long COVID) as well as participants with acute COVID infection.
  • The results to date indicate the participants appear to experience benefit after supplementation with 3CL protease inhibitor immune support supplement Tollovid.
  • Preliminary data from an ongoing IRB-waived study of customers who used the products to assist with their COVID and Long COVID were recently announced.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, Long COVID and, potentially, pediatric COVID-19.

Todos Medical Reports Pre-Print of Publication Detailing Tollovid Supplementation Following COVID-19 mRNA Vaccination in Long COVID

Retrieved on: 
Monday, August 15, 2022
U.S. Securities and Exchange Commission, GLOBE, Brain, Knowledge, RN, Research, Method, Patient, Monocyte, TBIA, Reardon, Ebola, Immune system, Technology, Neuron, Infection, Cell cycle, Lymphocyte, Biotechnology, Neurodegeneration, IRB, Pressure, OTCQB, Vaccine, Amazon, Preprint, RNA transfection, Apoptosis, Rabies virus, PASC, Cancer, Cell, MERS, COVID-19, Hospital, Synthase, Virus, ResearchGate, Vaccination, Solution, Severe acute respiratory syndrome coronavirus 2, PCR, Pardi, FDA, Legislation, Plasma, Zika virus, Company, TMB-2, Alzheimer's disease, Cancer immunotherapy, Pharmaceutical industry, Medical imaging, Pharma, COVID

There is an urgency for alternative solutions to provide protection against Long COVID.

Key Points: 
  • There is an urgency for alternative solutions to provide protection against Long COVID.
  • Tollovid has a 5-day dosing regimen, with 4 doses of 3 pills taken each day that provides maximum immune support.
  • Preliminary data from an ongoing IRB-waived study of customers who used the products to assist with their COVID and Long COVID were recently announced.
  • Tollovir will be developed for the treatment of hospitalized COVID-19 (severe and critical), moderate COVID-19, Long COVID and, potentially, pediatric COVID-19.

Todos Medical Completes Trial Design for Tollovid™ Long COVID Clinical Study in Adults

Retrieved on: 
Thursday, August 11, 2022
U.S. Securities and Exchange Commission, Vital signs, Trial of the century, GLOBE, Clinical trial, Brain, Knowledge, Research, Method, Immunoglobulin M, Patient, Monocyte, Contract, TBIA, Immune system, Entrepreneurship, Part, Neuron, Technology, Cell cycle, Immunoglobulin A, Lymphocyte, Șaeș, Biotechnology, Neurodegeneration, Safety, IRB, Pressure, OTCQB, Amazon, Apoptosis, COVID, Cancer, Synthase, MERS, COVID-19, CRP, Capsule, Virus, Solution, Severe acute respiratory syndrome coronavirus 2, PCR, Legislation, Immunoglobulin G, Biomarker, Plasma, Company, TMB-2, Alzheimer's disease, Intention, VEGF, Cancer immunotherapy, Pharmaceutical industry, Medical imaging, Pharma, Long COVID

New York, NY, and Tel Aviv, ISRAEL, Aug. 11, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd has finalized plans for a proposed safety and efficacy clinical trial for its 3CL protease inhibitor immune support dietary supplement Tollovid™ in patients with Long COVID. The 45-patient Part A of the study will be conducted as a 3-arm, randomized, controlled, observer-blinded clinical study evaluating Tollovid’s effects on the structure/function of the immune system as measured by the presence of neutralizing antibodies, total anti SARS-CoV-2 antibodies (IgG, IgA, IgM) and VEGF cytokine levels.  Participating subjects will be randomized into three cohorts: 1) a 15-patient cohort to receive 30-day treatment regimen of 12 capsules per day; 2) a 15-patient cohort to receive a 15-day treatment regimen of 12 capsules per day, followed by 15-day treatment regimen of 6 capsules per day; and 3) an untreated control group who will be eligible to receive Tollovid at the conclusion study. All three groups will be allowed to continue taking their standard of care medications while on study, with the exception of other 3CL protease inhibitors.  3CL Pharma intends to initiate this clinical study in early fourth quarter of 2022. Two Long COVID clinics are in the process of finalizing contracts to participate in the study. It is the intention that study participants can enroll and be evaluated both virtually via remote monitoring, as well as in person.

Key Points: 
  • Two Long COVID clinics are in the process of finalizing contracts to participate in the study.
  • It is the intention that study participants can enroll and be evaluated both virtually via remote monitoring, as well as in person.
  • The secondary structure/function endpoints of Part A of the study are changes in the Amerimmune/Provista Long Covid Panel, CRP and VEGF after administration of Tollovid at day 30 following enrollment.
  • Preliminary data from an ongoing IRB-waived study of customers who used the products to assist with their COVID and Long COVID were recently announced.

Todos Medical Announces First Long COVID Clinic Laboratory Services Agreement for Long COVID Panel Biomarker Partnership with Amerimmune Diagnostics

Retrieved on: 
Friday, August 5, 2022
U.S. Securities and Exchange Commission, Medicare, GLOBE, Brain, Research, Knowledge, Method, Patient, Monocyte, TBIA, Immune system, Diagnosis, Neuron, Technology, Cell cycle, Lymphocyte, Partnership, Biotechnology, Neurodegeneration, IRB, Pressure, OTCQB, Physician, Apoptosis, COVID, GA, Cancer, Synthase, MERS, COVID-19, Virus, Solution, Severe acute respiratory syndrome coronavirus 2, PCR, Legislation, Population, Lists of diseases, Plasma, Company, TMB-2, Alzheimer's disease, Todos, Cancer immunotherapy, Long COVID, Quest Diagnostics, Vaccine, Pharmaceutical industry, Medical imaging, Pharma

New York, NY, and Tel Aviv, ISRAEL, Aug. 05, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced the first commercial patient samples have been received for its Long COVID Panel biomarker partnership between its CLIA/CAP certified lab Provista Diagnostics and Amerimmune Diagnostics, a CLIA/CAP certified laboratory with expertise in immune diagnostics and a leader in the field of clinical immunology and immune assessment of acute and long-COVID. The patient samples received were requisitioned by Long COVID Clinic RTHM (Real Time Health Monitoring), the partnership’s first Long COVID Clinic client, collected at a Quest Diagnostics service center in the United States and shipped to Amerimmune’s lab in McLean, Virginia for processing. The cPass neutralizing antibody and total antibody portion of the panel is being subcontracted to Provista in Atlanta, GA and the data sent back to Amerimmune to include in their report back to the RTHM physician. The various biomarker tests included in the Long COVID Panel are covered by commercial insurance and Medicare.

Key Points: 
  • The various biomarker tests included in the Long COVID Panel are covered by commercial insurance and Medicare.
  • The objective is for Long COVID Panel data to be included in Todos ongoing Tollovid case study series going forward to corroborate perceived patient benefit.
  • Founded in 2010, Amerimmune Diagnostics focuses on immunological testing as a solution to the unmet need and timely diagnosis of immune disorders.
  • Preliminary data from an ongoing IRB-waiver study of customers who used the products to assist with their COVID and Long COVID was recently announced.

Todos Medical Announces Preprint of Acute COVID-19 Paxlovid Rebound Rescued by Tollovid

Retrieved on: 
Monday, August 1, 2022
Ivermectin, Ritonavir, Legislation, Apoptosis, Company, Method, CDC, COVID Symptom Study, PCR, Brain, Severe acute respiratory syndrome coronavirus 2, Knowledge, Cancer immunotherapy, U.S. Securities and Exchange Commission, Research, Solution, Cell cycle, TBIA, Symptoms of COVID-19, Biotechnology, Technology, Synthase, ResearchGate, IC50, Virus, Monocyte, GLOBE, PASC, Outline, MERS, Immune system, COVID-19, Preprint, Recurrence, Cancer, OTCQB, Pressure, Plasma, Neuron, Lymphocyte, Alzheimer's disease, RN, Neurodegeneration, Patient, TMB-2, Pharmaceutical industry, Vaccine, Medical imaging, Pharma, COVID

Here we outline a case of SARS-CoV-2 re-infection in a Long COVID patient treated with Paxlovid.

Key Points: 
  • Here we outline a case of SARS-CoV-2 re-infection in a Long COVID patient treated with Paxlovid.
  • The subject reported rebound symptoms immediately after completing a 5-day course of Paxlovid.
  • In this case study, we outline subsequent supplementation with Tollovid, a botanical 3CL protease inhibitor immune support supplement, resulting in resolution of acute COVID symptoms.
  • Tollovid and Tollovid Daily bind to the active site (receptor binding domain) of the 3CL protease.